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Abstract Expression of myelin basic protein (MBP) and Po
gene products is induced during the final postnatal maturation of
Schwann cells and reinduced during nerve regeneration. We show
that a chimeric protein containing interleukin-6 fused to its
soluble receptor (IL6RIL6 chimera) induces MBP and Po RNAs
and proteins in cultures of dorsal root ganglia (DRG) from 14 day
old mouse embryos. Activation of gp130 signaling by IL6RIL6
appears comparable to cyclic AMP elevating agents to induce the
myelin gene products in DRG and in pure Schwann cell cultures.
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1. Introduction
Neuroprotective e¡ects of interleukin-6 (IL-6) have been
observed in cultures of cholinergic and catecholaminergic
brain neurons (see [1,2] for review). Sympathetic neurons
from the superior cervical ganglia [3] and sensory neurons
of embryonic dorsal root ganglia (DRG) [4] respond by in-
creased survival and neurite outgrowth when IL-6 is provided
in combination with soluble IL-6 receptor (sIL-6R). This com-
bination is needed, because in many cell types having or lack-
ing membranal IL-6R, exogenous sIL-6R acts as an agonist of
IL-6 by promoting the dimerization of gp130 which carries
out the signal transduction [5^7]. For various neurons, the IL-
6 and sIL-6R combination has an e¡ect similar [3,4] to that of
other neuropoietic cytokines such as CNTF and LIF signaling
through gp130 in conjunction with the LIF receptor [8^10].
Forms of sIL-6R are present in body £uids [6,11] and act as
IL-6 agonists also in vivo. In particular, transgenic mice over-
expressing IL-6 and sIL-6R exhibit accelerated regeneration
of axotomized hypoglossal nerve [4]. In wild-type mice, IL-6 is
upregulated in the Schwann cells (SC) distal to the nerve
lesion as well as in the neuronal bodies of the hypoglossal
nuclei which also produce more IL-6R [4]. SC in contact
with neurons produce IL-6 and there is a further increase of
IL-6 within 12 h after sciatic nerve crush, highest distally to
the site of injury [12]. IL-6 and IL-6R mRNA expressions
increase in DRG during the postnatal period of myelination,
mainly in neurons but also in SC for IL-6R mRNA [13].
Unlike IL-6, the CNTF levels in SC fall following axotomy,
reincreasing only when the nerves regenerate [14,15]. While it
is generally assumed that these cytokine changes contribute
mainly to neuron survival [2^4,8], we were interested in their
role in myelination. Following nerve lesions, myelinating SC
(mSC) dedi¡erentiate to non-myelinating SC (nmSC) that ex-
press glial ¢brillary acidic protein (GFAP) like embryonic SC
(eSC), and proliferate as an essential part of nerve regenera-
tion [16^19]. Remyelination requires di¡erentiation of nmSC/
eSC to mSC expressing myelin genes, this being a reversible
axon-dependent process analogous to the postnatal matura-
tion of eSC into mSC [17,18]. One agent able to induce pe-
ripheral nerve myelin gene products such as Po and myelin
basic protein (MBP) in isolated SC is forskolin, which in-
creases intracellular cAMP [16,18]. CNTF administered in
vivo potentiates sciatic nerve regeneration and remyelination
[20], but this may be secondary to neuroprotective e¡ects since
in vitro e¡ects on myelin synthesis were not shown.
We examined the e¡ect of IL-6 type signaling on myelin
genes expression in embryo DRG cultures, in which Hirota
et al. [4] showed increased neurite extensions by IL-6 and sIL-
6R. The IL-6 type signal can be most e⁄ciently delivered by
recombinant proteins linking sIL-6R to IL-6 [3,21,22]. We
used here a mammalian cell-produced IL6RIL6 chimera
where human sIL-6R is directly fused to IL-6 [22] and which
has a higher a⁄nity for gp130 than IL-6 with sIL-6R [23].
This molecule enhanced axon sprouting from DRG as did
nerve growth factor (NGF) but, in addition, IL6RIL6 induced
expression of the MBP and Po gene products in SC.
2. Materials and methods
DRG explants were prepared [24] from C57Bl6/Sv129 F1 mice em-
bryos at day E14 and cultured on glass coverslips coated with rat tail
type VII collagen, or with poly-L-lysine, MW 30^70 000 (both from
Sigma, St. Louis, MO, USA). The coverslips were placed in Nunc 12
well plates in 0.5 ml DMEM/F12 (1/1) with 10% fetal calf serum
(FCS) and 2% horse serum, at 37‡C in 5% CO2. Additions were either
1.5 Wg/ml rhIL6RIL6 chimera, produced in CHO cells as an 85 kDa
glycoprotein [22,25], or 1 Wg/ml rhIL-6 also from CHO cells [22], or
mouse NGF 7S from submaxillary glands (Sigma) at 50^100 ng/ml, or
forskolin 20 WM (Sigma). DRG were similarly cultured from Lewis rat
embryos or newborns, but with a change on day 3 to MEM with 15%
FCS and 50 Wg/ml ascorbic acid to enhance myelination [26]. An SC
line, cloned from primary cultures of newborn mouse sciatic nerve
cells transfected by mutant p53 and neomycin resistance genes, and
veri¢ed to align on demyelinated neurons in vitro, was kindly pro-
vided by Dr. Bernard Attali, Neurobiology Department, Weizmann
Institute of Science.
DRG cultures were ¢xed in 2% paraformaldehyde, 0.1% glutaral-
dehyde, 0.1% tannic acid in PBS for 1 h at 20‡C and treated with
0.1% Triton X-100, 10% goat serum for 2 h before immunostaining.
Anti-MBP monoclonal antibody (MAB 386, Chemicon, Temecula,
CA, USA) or anti-Po MAB (gift of Dr. Kitamura [27]) were added
in 1% goat serum for 1 h at 37‡C, followed by goat anti-mouse IgG
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 0 4 0 - 6
*Corresponding author. Fax: (972) (8) 9344108.
E-mail: lvchebath@weizmann.weizmann.ac.il
1 Also corresponding author.
FEBS 22486 25-8-99
FEBS 22486FEBS Letters 457 (1999) 200^204
(L+H)-Alexa 488 £uorescent dye conjugate (Molecular Probes, Eu-
gene, OR, USA) for 1 h. Mowiol (Calbiochem) mounted slides were
photographed (Olympus IX-70, Tokyo, Japan). Osmicated (0.1%
OsO4) Sudan black B stained preparations were observed as described
[24,28].
Total cell RNA was extracted from pools of 5^10 DRG 8 day
cultures by guanidinium thiocyanate-phenol-chloroform with the
Tri-Reagent kit (Molecular Research Center, Cincinnati, OH, USA)
and precipitated in isoamyl alcohol. Reverse transcriptase (Super-
scriptII, Gibco-BRL) reactions were done in 20 Wl with samples of
0.4 Wg RNA, 0.5 Wg oligo-dT primers (Promega) and 1^3 Wl of the
reaction used to amplify the cDNAs fragments with Dynazyme Taq
polymerase (Finnzymes, Finland). Mixes with MgCl2 contained
0.3 WM oligo nucleotide primers, 200 WM dNTPs and cycles were
30 s at 94‡C, 45 s at 58‡C, 1 min at 75‡C. After 25^30 cycles (linear
detection), the products were extended by 5 min incubation at 72‡C.
For murine MBP RNA, the primers were: forward, 5P-CACGGG-
CATCCTTGACTCCA and reverse, 5P-GAGATCCAGAGCGGC-
TGTCT. The major bands ampli¢ed were 345 bp and 240 bp long,
corresponding to splicing forms of MBP and Golli-A transcripts [29].
For murine Po mRNA, the primers were: forward, 5P-GCTCTTCTC-
TTCTTTGGTGCTGTCT and reverse, 5P-GGCGTCTGCCGCCCT-
CGCTTCG, amplifying a 653 bp fragment [30]. Polymerase chain
reaction (PCR) with G3PDH commercial primers (Clontech, Palo
Alto, CA, USA) was used as control in each reaction. The intensities
of the 345 bp MBP fragment and 653 bp Po fragments were quanti-
¢ed by the AlphaEase program (Alpha Innotech, San Leandro, CA,
USA). The values were normalized for the G3PDH band using the
same reverse transcription (RT) reaction.
3. Results
DRG of mouse E14 embryos were cultured on collagen
coated coverslips and examined in phase contrast. Addition
of IL6RIL6 induced the sprouting of axons from the DRG,
which was visible already after 1 day (Fig. 1B). The number of
axons was strikingly higher than without IL6RIL6 (Fig. 1A).
Treatment of the DRG by NGF also increased the axonal
growth markedly (Fig. 1C). However, when compared to
the NGF treatment, the DRG cultures that had been treated
by IL6RIL6 had a di¡erent morphology. There were more
elongated cells adjacent to the axons giving a thicker appear-
ance to the neural extensions (Fig. 1B). Treatment by IL6-
RIL6 modi¢ed also the morphology of more mature rat E19
DRG that were cultured for 14 days, with addition of ascor-
bic acid, and then stained with Sudan black to examine myelin
sheaths. With IL6RIL6 (Fig. 1D), the cultures contained
stained smooth nerve ¢bers with the typical increased diame-
ter and sti¡ness, as described by Bunge et al. [28] for mye-
linating nerve ¢bers in DRG. In contrast, NGF treated DRG
(Fig. 1E) showed irregularly shaped thinner axon ¢bers, with
poor Sudan black staining and more closely spaced SC, which
are characteristics of the premyelinating phase [28].
These observations suggested that IL6RIL6 not only sus-
Fig. 1. Morphology of DRG cultures. A^C: Mouse E14 DRG on collagen after 1 day, phase contrast, magni¢cation U100. A: non-treated,
B: with IL6RIL6, C: with NGF. D,E: Rat E19 DRG on poly-lysine for 14 days with ascorbic acid added at day 3, Sudan black stain, bright-
¢eld, magni¢cation U400. D: with IL6RIL6, E: with NGF.
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tains axon growth from the DRG explants but also a¡ects
development of the SC progenitors and their capacity to pro-
duce myelin components. Indeed, RNA extracted from mouse
E14 DRG after 8 days of culture with IL6RIL6 showed an
over 20-fold increase in transcripts from the major peripheral
nerve myelin protein gene Po when analyzed by RT-PCR
(Fig. 2A). In comparison, IL-6 alone had little e¡ect. NGF-
treated DRG also showed some increase in Po RNA over
untreated cultures, but addition of IL6RIL6 together with
NGF strongly increased the levels of Po RNAs as comparison
to NGF alone (Fig. 2A). The IL6RIL6 treatment also in-
creased the MBP RNA levels in the mouse E14 DRG cultures
(Fig. 2A, right panel). The activity of IL6RIL6 was compa-
rable to that of a cAMP elevating agent, such as forskolin,
known to induce MBP gene transcripts in SC [16]. In contrast,
treatment of the DRG cultures by NGF had little e¡ect on
MBP RNA and IL-6 alone had no e¡ect (Fig. 2A).
Since myelination is a process that depends on contact of
SC with axons [16], the induction of MBP RNA in the IL6-
RIL6-treated DRG cultures may result from an e¡ect on axon
development. In order to examine the ability of IL6RIL6 to
induce expression of the MBP gene in pure cultures of SC, we
used a line of immortalized SC that had been isolated from
sciatic nerve of newborn mice. Treatment of these cells by
IL6RIL6 induced MBP gene transcripts within 24 h as meas-
ured by normalized RT-PCR (Fig. 2B). The activity of IL6-
RIL6 was comparable to or higher than that of forskolin at 24
and 72 h (Fig. 2B).
Immunostaining with antibodies to myelin basic protein
identi¢ed myelinating SC in the DRG cultures. IL6RIL6
treated mouse E14 DRG cultures (at 9 days) showed many
cells positive for MBP, whereas such cells were not apparent
in the NGF treated cultures (Fig. 3A^D), nor in the untreated
cultures (not shown). With IL6RIL6, the MBP-positive cells
were elongated and formed aligned patterns as typical of dif-
ferentiated SC. This e¡ect of IL6RIL6 on increasing the num-
ber of non-neuronal cells with elongated processes was con-
sistently observed throughout the study. Immunostaining also
con¢rmed the induction of the Po protein in IL6RIL6 treated
DRG as comparison to non-treated or to NGF treated cul-
tures. A marked increase in cells positive for the Po protein
was produced by IL6RIL6 in both E14 DRG (not shown),
and newborn rat DRG cultured 8 days with addition of as-
corbic acid (Fig. 3E), as comparison to the same cultures with
NGF (Fig. 3F). By phase contrast, the NGF cultures showed
many SC attached to axons but negative for Po (not shown).
Hence, the IL6RIL6 recombinant cytokine acts as an inducer
of myelin gene products for SC, in addition to its e¡ect on the
neuronal cells.
4. Discussion
In the mouse embryo at days E12.5^E16, the neural crest
derived precursors develop into committed embryonic eSC,
positive for the S100 protein, but the MBP and Po gene prod-
ucts are late markers that are strongly induced only when the
eSC mature into myelinating mSC after birth [17,18,31]. These
late myelination markers are not formed by SC from Krox-20
de¢cient mice, which express S100 and early myelination
markers [32]. In this study, we show that mouse E14 DRG
cultures were induced to express Po and MBP RNA and
proteins when treated with the IL6RIL6 chimera. Unlike the
transition from precursors to eSC, the maturation of eSC to a
myelinating phenotype is reversible as seen after nerve lesions,
and is stimulated by interaction of SC with axons [16^18].
Whereas the IL-6 type signal from IL6RIL6 did promote
neurite outgrowth from DRG explants, in line with Hirota
et al. [4], the stimulation of axonal growth by NGF did not
cause the marked induction of the Po and MBP gene products
obtained with IL6RIL6. Furthermore, IL6RIL6 was also ac-
tive to rapidly induce MBP gene transcripts in cultures of
isolated SC. Although these SC were an immortalized line,
this result shows some direct e¡ect of the cytokine on SC
cultured without neurons. The levels of MBP RNA reached
were similar to those produced by using forskolin to increase
cAMP levels, a treatment which palliates the absence of neu-
rons [16]. Elevation of cAMP was reported to induce MBP
gene expression in a SC line through a MAP kinase dependent
pathway [33]. Signaling through gp130 activates in various
cells the JAK/Stat pathway as well as the MAP kinase and
PI 3-kinase pathways [34]. However, the mechanism by which
IL6RIL6 induces MBP and Po in SC remains to be deter-
mined. We recently found that IL6RIL6 downregulates Pax-
3 and induces MBP and other myelin proteins in transdi¡er-
entiating melanoma cells [25]. Pax-3 is a repressor of MBP
gene expression [35], but there is no evidence that IL6RIL6
acts in this way on SC.
In the mouse E14 DRG cultures, IL6RIL6 increased the
number of non-neuronal cells with elongated cell processes
typical of the SC phenotype. With more mature newborn
rat DRG, IL6RIL6 promoted the formation of Sudan black
stained nerve ¢bers with the characteristics of myelinating
¢bers [28]. We have observed this in cultures with or without
ascorbic acid, which helps lamina formation, Po synthesis and
myelination [26]. These morphological changes support the
notion that IL6RIL6 acts as a maturation factor for mSC.
Other mechanisms cannot be excluded since constitutive ex-
Fig. 2. Myelin Po and MBP gene transcripts. A: Mouse E14 DRG
on poly-lysine after 8 days. B: Culture of isolated mouse SC line.
The intensity of the Po and MBP RT-PCR products was normal-
ized for the G3PDH bands. The fold increase over the non-treated
culture value (taken as 1) is shown for each condition. Forsk: for-
skolin.
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pression of Po and MBP was reported in rat postnatal SC
cultures without serum [36] and it was suggested that inhib-
itors account for the absence of myelin gene products in early
DRG. The e¡ect of IL6RIL6 may then be to overcome this
inhibition. However, this constitutive expression is a low basal
level seen also in neural crest cells and eSC [37]. It is clear that
the Po and MBP expression observed here is not a constitutive
basal level since IL6RIL6 was an as e⁄cient inducer as for-
skolin, which is a recognized mSC maturation stimulus
[16,17,37,38]. Another possibility is that IL6RIL6 acts as a
SC growth factor. The main growth and survival factors for
precursors and eSC are the L-neuregulins/glial growth factors
(NRGL/NDFL-2/GGF), working with ¢broblast growth fac-
tor-2 (FGF-2) [39]. Neuregulins inhibit Po and MBP expres-
sion [36], and so does FGF-2 [40], in contrast to the IL6RIL6
stimulation demonstrated here. Other growth factors such as
insulin-like growth factors IGF-I, and neurotrophins such as
NT-3, BDNF and NGF, have also been reported not to in-
duce late myelin markers unless forskolin is added [17]. IL6-
RIL6 may stimulate SC maturation but also have a growth
e¡ect, since CNTF and LIF have indirect growth e¡ects on
SC through induction of the SC mitogen Reg-2 in neurons
[19]. The mSC maturation functions of CNTF and LIF are
still unclear. In DRG cultures, CNTF and LIF synergize with
bFGF to induce Krox-20, but this transcription factor is still
an eSC marker that is also induced by NDFL-2 [41]. In cul-
tures of oligodendrocyte-astrocyte progenitors, CNTF and
LIF appear to increase survival of MBP oligodendrocytes
but they induce more strongly astrocytes that are GFAP
like nmSC [42^44]. Our results show for the ¢rst time that
the IL-6 type signal produced by IL6RIL6 allows SC to
undergo in vitro a late stage of di¡erentiation to myelinating
cells, characterized by the induction of MBP and Po gene
products.
Fig. 3. Immuno£uorescence for MBP and Po proteins. A^D: Mouse E14 DRG on collagen after 9 days stained with anti-MBP. E^F: Rat new-
born DRG on poly-lysine for 7 days with ascorbic acid added at day 3, stained with anti-Po. A,B,E: with IL6RIL6, C,D,F: with NGF. Mag-
ni¢cation U200. A,C: Phase contrast; B,D,E,F: Ultraviolet light.
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In vivo, IL-6 injections appeared to reduce demyelination in
the murine encephalomyelitis produced by Theiler’s virus in-
fection [45]. However, this may be rather an immune mediated
reduction of the virus pathogenic e¡ect. In the hypoglossal
nerve regeneration, by overexpression of IL-6 and sIL-6R
[4], myelination was not examined. Based on our results, acti-
vation of gp130 by the IL6RIL6 chimera should be an inter-
esting modality to study in vivo for stimulating remyelination
in models of nerve regeneration [20,46] or of autoimmune
demyelination of the central nervous system [47], in which
GGF [46,47] and CNTF [20] have shown activity.
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